

27 November 2017

Announcements  
National Stock Exchange of Australia  
PO Box 283  
NEWCASTLE NSW 2300

**Market Announcement – 2017 Annual General Meeting Chairman Opening Address**

Enclosed is a copy of the Opening Address, to be presented by Kosmas Dimitriou (Chair of IQX Limited), at 10:30am on 27th November 2017, at the IQX Limited Annual General Meeting to be held at the Grace Hotel, Sydney.

A handwritten signature in black ink, appearing to read 'Gerardo Incollingo'.

**Gerardo Incollingo**  
Company Secretary

**iQX Investments**

Eradicating disease through capital investment

iQX Investments is an investment company and fund manager specialising in the life science sector, supporting physicians, scientists and entrepreneurs who are building innovation based businesses.

## **Chairman's Opening Address**

On behalf of the board of directors, it is an honour and privilege to provide a review of iQX Limited for the financial year ended 30 June 2017.

The iQX team has successfully continued to translate the Company's strategy, into tangible deliverables including:

- The realisation of good value investment at the early stage;
- The expansion of our infrastructure, in particular the unconditional approval of the Series 8 Life Science Fund thereby enabling further investment into biotechnology opportunities; and
- The creation of significant value from prior investments as per the operational and financial review.

The financial results for the year ended 30 June 2017 are encouraging and reflect the on-going investment and development of iQX Limited's early stage biotechnology assets.

iQX Limited is always seeking to deliver value to all its stakeholders and to ensure that we partner with the iQ Group of companies to identify and invest into sustainable early stage biotechnology investments, on a global scale in order to continue the journey of eradicating disease through capital investment.

We are confident that our entrepreneurial, curious and innovative iQX team, led by an aspirational and committed group of executive management and board members, can deliver on the clear mandate to build the iQX business and make a real difference within the Australian Life Science sector.